Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $9.75, but opened at $9.2950. Sysmex shares last traded at $9.3050, with a volume of 93,323 shares traded.

Analyst Upgrades and Downgrades

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold”.

Sysmex Price Performance

The stock has a market capitalization of $5.96 billion, a P/E ratio of 24.92 and a beta of 1.07. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The stock has a 50-day simple moving average of $8.85 and a 200 day simple moving average of $9.08.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The firm had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities analysts forecast that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.